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Background/aim: Thyroid cancer is the most common endocrine malignancy. Recently the incidence has been increasing faster
compared to other malignancies. Different studies have shown that the incidence of breast cancer in patients followed due to thyroid
cancer has increased, and vice versa. The aim of this study was to evaluate the frequency of second primary cancers in the follow-up of
patients with thyroid cancer.
Materials and methods: In this study, 1196 patients with thyroid cancer were evaluated in the Necmettin Erbakan University Meram
Medical School’s Department of Endocrinology between 2004 and 2018. Demographic characteristics and radiological and pathological
results of the patients were recorded. The presence of accompanying second malignancies in patients with thyroid cancer was investigated.
Results: In our study, 985 (82.4%) women (mean age: 46.1 ± 13.3 years) and 211 (17.6%) men (mean age: 49.9 ± 14.2 years) were
evaluated. The median follow-up was 63 months (2–164 months). Of the 1196 patients, 1126 (94.1%) had no additional cancer and 70
(5.9%) patients had a second malignancy. The accompanying second malignancies were breast cancer in 24 (2%) patients, skin cancer
in 8 (0.7%) patients, renal cell cancer in 5 (0.4%) patients, lung cancer in 5 (0.4%) patients, colon cancer in 5 (0.4%) patients, lymphoma
in 5 (0.4%) patients, endometrial cancer in 4 (0.3%) patients, and 14 cases of other rare types of cancer.
Conclusion: In our study, it was found that the most common second primary malignancy in patients with thyroid cancer was breast
cancer. However, other cancers (skin cancer, renal cell cancer, lymphoma, and colon, lung, or endometrial cancer) may occur in patients
with thyroid cancer.
Key words: Thyroid cancer, second primary cancer, breast cancer

1. Introduction
Thyroid cancer is the most common endocrine malignancy.
The incidence continues to increase worldwide [1]. Thyroid
cancer accounts for approximately 1.0%–1.5% of all new
cancer cases [2]. It is most common in women between
the ages of 30 and 70 and is 2.9 times more likely to occur
in women than in men. Although the incidence of thyroid
cancer is increasing, mortality due to thyroid cancer is
decreasing. This is because of early diagnosis and effective
treatment with surgery and radioactive iodine (RAI)
treatment [3]. More than 90% of thyroid cancers comprise
differentiated thyroid cancers, including papillary and
follicular carcinoma types [4]. Less common types of
thyroid cancers are medullary thyroid cancer (5%–9%) and
anaplastic thyroid cancer (1%–2%) [5].
Increased incidence of thyroid cancer and good
prognosis has raised concerns about the development of

second primary cancers, especially after RAI treatment.
In addition, thyroid cancers may also occur as secondary
neoplasms after other cancers. Different studies have
shown that the incidence of breast cancer in patients
followed due to thyroid cancer has increased and also
the risk of thyroid cancer has increased in the long-term
follow-up of breast cancer patients. It has also been found
that the risk of other second primary cancers, such as
prostate, kidney, and adrenal cancer, increases in thyroid
cancer patients [6–8]. The aim of this study was to evaluate
the frequency of second primary cancers in the follow-up
of patients with thyroid cancer.
2. Materials and methods
A total of 1196 patients who were followed with the
diagnosis of thyroid cancer between 2004 and 2018
were included in the retrospective study. The Necmettin
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Erbakan University Meram Medical School Ethics
Committee approved the study with approval no.
2018/1647 dated 04.01.2019. The demographic, clinical,
radiological, and pathological data of the patients were
recorded from the patient files. No patients had a history
of thyroid or neck surgery for nonthyroidal cancer or neck
irradiation. Papillary thyroid carcinomas measuring 10
mm or less in diameter were classified as papillary thyroid
microcarcinoma. The presence of a second accompanying
malignancy of patients was investigated.
2.1. Statistical analysis
Statistical analysis was performed using SPSS 22.0 (IBM
Corp., Armonk, NY, USA). Continuous variables were
given as mean ± standard deviation if the distribution
was normal, and as median (minimum–maximum) if
the distribution was not normal. In the comparison of
independent groups’ differences, the significance test of the
difference between the two means (independent samples
t-test) was used when the parametric test assumptions
were met. The Mann–Whitney U test was used to compare
independent groups’ differences when the parametric test
assumptions were not provided. For differences, P < 0.05
was considered statistically significant.
3. Results
The study population included 1196 patients, 985 (82.4%)
of whom were female and 211 (17.6%) of whom were
male. The mean age of women was 46.1 ± 13.3 years
and the mean age of men was 49.9 ± 14.2 years. The
median follow-up was 63 months (2–164 months). The
pathological diagnoses were papillary microcarcinoma

in 375 (31.4%) patients, papillary thyroid cancer in 732
patients (61.2%), follicular thyroid cancer in 38 (3.2%)
patients, medullary thyroid cancer in 19 (1.6%) patients,
papillary microcarcinoma and medullary thyroid cancer
in 2 (0.2%) patients, undifferentiated thyroid cancer in
3 (0.3%) patients, less differentiated thyroid cancer in
2 (0.2%) patients, and Hurthle cell cancer in 25 (2.1%)
patients (Figure 1). Of the 1196 patients, 1126 (94.1%) had
no additional cancer and 70 (5.9%) had a second primary
malignancy.
Of the 70 patients with a second primary malignancy,
55 (78.6%) were female and 15 (21.4%) were male. The
mean age of female patients was 52.1 ± 10.6 years and
the mean age of male patients was 61.8 ± 11.6 years. The
mean age of the male patients was significantly higher than
that of the female patients (P = 0.003). The mean followup period for thyroid cancer was 61.8 ± 39.2 months
and the mean follow-up period for the second primary
malignancy was 69.5 ± 48.9 months. Of these 70 patients,
23 (32.9%) had papillary microcarcinoma, 42 (60%) had
papillary thyroid cancer, 4 (5.7%) had follicular thyroid
cancer, and 1 (1.4%) had undifferentiated thyroid cancer
(Figure 2). The accompanying second malignancies were
breast cancer in 24 (2%) patients, skin cancer in 8 (0.7%)
patients, renal cell cancer in 5 (0.4%) patients, lung cancer
in 5 (0.4%) patients, colon cancer in 5 (0.4%) patients,
lymphoma in 5 (0.4%) patients, endometrial cancer in 4
(0.3%) patients, and other rare cancer types in 14 patients
(Table).
Of the 1196 patients included in our study, 855
(71.5%) received RAI treatment and 341 (28.5%) did
Papillary microcarcinoma 31.4%
Papillary thyroid cancer 61.2%
Follicular thyroid cancer 3.2%

Medullary thyroid cancer 1.6%
Papillary microcarcinoma and
medullary thyroid cancer 0.2%
İUndifferentiated thyroid cancer
0.3% 0.3
Less differentiated thyroid
cancer 0.2% 0.2
Hurthle cell cancer 2.1%
Figure 1. Thyroid cancer pathological subtypes of all patients.
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Papillary microcarcinoma 32.9%

Papillary thyroid cancer 60%

Follicular thyroid cancer 5.7%

Undifferentiated thyroid
cancer 1.4%
Figure 2. Thyroid cancer pathological subtypes of patients in whom second primary malignancy was detected

not. The median dose of RAI treatment was 150 mCi
(min–max: 100–800) and mean RAI treatment dose was
146 ± 73 mCi. Of the 70 patients with second primary
malignancies, 32 were diagnosed with thyroid cancer first
and then diagnosed with the second primary malignancy.
Of these 32 patients, 25 received RAI treatment. The
median RAI dose of patients who received RAI was 150
mCi (min–max: 100–650); mean RAI dose was 181 ±
144 mCi. These patients were diagnosed with a second
primary malignancy after a mean of 39 ± 33 months after
thyroid cancer diagnosis (median: 38 months; min–max:
1–118 months). Of the 70 patients with a second primary
malignancy, 38 were diagnosed with the malignancy prior
to thyroid cancer and 25 of these patients had RAI. The
median RAI dose of patients who received RAI was 150
mCi (min–max: 100–400); mean RAI dose was 160 ±
68 mCi. There was no difference between patients with
another malignancy prior to thyroid cancer diagnosis and
those diagnosed with a second primary malignancy after
thyroid cancer diagnosis in terms of RAI dose (P= 0.473).
4. Discussion
Thyroid cancer is the most common endocrine
malignancy. Recently, the incidence of thyroid cancer has
increased faster than that of other cancers. Despite the
increased incidence of thyroid cancer, early diagnosis and
effective use of treatment modalities such as surgery and
RAI treatment have decreased mortality [3]. Increased
incidence of thyroid cancer and good prognosis have
raised concerns about the development of second primary
malignancies, especially after RAI treatment. The reasons
for the increased risk of second primary malignancies in
patients with thyroid cancer are not fully known. Possible
causes include RAI treatment, age, genetic predisposition,
hormonal changes, and smoking [9–11].
In a study of 2031 patients with differentiated thyroid
cancer, Silva et al. found that the mean age of thyroid
cancer patients was 48 years, 83% were female, and 17%

Table. Second primary cancers in the follow-up of patients with
thyroid cancer.
Second primary cancer

n (%)

Breast cancer

24 (2%)

Skin cancer

8 (0.7%)

Lung cancer

5 (0.4%)

Colon cancer

5 (0.4%)

Renal cell cancer

5 (0.4%)

Lymphoma

5 (0.4%)

Endometrial cancer

4 (0.3%)

Prostate cancer

3 (0.3%)

Ovarian cancer

3 (0.3%)

Carcinoid tumor

1 (0.1%)

Parotid cancer

1 (0.1%)

Bladder cancer

1 (0.1%)

Kaposi’s sarcoma

1 (0.1%)

Gastric cancer

1 (0.1%)

Hairy cell leukemia

1 (0.1%)

Nasopharyngeal cancer

1 (0.1%)

Central nervous system cancer

1 (0.1%)

were male [12]. In our study 1196 patients were included,
82.4% of whom were female and 17.6% of whom were
male. The mean age of women was 46.1 ± 13.3 years and
the mean age of men was 49.9 ± 14.2 years.
In the study of Izkhakov et al., 1032 patients with
thyroid cancer were included and 85.4% of the patients
had papillary thyroid cancer, 9.2% had follicular thyroid
cancer, 3.4% had medullary thyroid cancer, and 1.9% had
less differentiated thyroid cancer. In their study, a second
primary malignancy was found in 8.9% of patients. In their
study, breast, brain, urinary system, and lung cancers in
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women and urinary system and prostate cancers in men
were found to be the accompanying cancer types [13]. In
the study of Silva-Vieira et al., a second malignancy was
detected in 6.4% of 2031 differentiated thyroid cancer
patients. Forty (1.9%) patients had breast, 24 (1.1%)
had genitourinary, 23 (1.1%) had gastrointestinal, 12
(0.5%) had hematologic, and 12 (0.5%) had lung-pleural
cancer [9]. In our study, in terms of thyroid cancer
subtypes, 92.6% of patients had papillary thyroid cancer,
3.2% had follicular thyroid cancer, 1.6% had medullary
thyroid cancer, 0.2% had papillary microcarcinoma and
medullary thyroid cancer, 0.3% had undifferentiated
thyroid cancer, 0.2% had less differentiated thyroid
cancer, and 2.1% had Hurthle cell thyroid cancer. In our
study, the rate of second primary malignancies in thyroid
cancer patients was 5.9%. We found breast cancer in 24
(2%) patients, skin cancer in 8 (0.7%) patients, renal
cell cancer in 5 (0.4%) patients, lung cancer in 5 (0.4%)
patients, colon cancer in 5 (0.4%) patients, lymphoma
in 4 (0.3%) patients, endometrial cancer in 4 (0.3%)
patients, and other rare cancers in 14 patients.
In their study, Sandeep et al. showed that there was
a second primary malignancy in 2821 of 39,002 patients
with thyroid cancer. When thyroid cancer patients with
accompanying second malignancies were examined in
terms of subtypes of thyroid cancer, they found that 39.8%
had papillary thyroid cancer, 13.5% had follicular thyroid
cancer, and 3% had medullary thyroid cancer [7]. In our
study, of the 70 patients with thyroid cancer who had a
second primary malignancy, 23 (32.9%) had papillary
microcarcinoma, 42 (60%) had papillary thyroid cancer,
4 (5.7%) had follicular thyroid cancer, and 1 (1.4%) had
undifferentiated thyroid cancer. In the metaanalysis of
Nielsen et al., the risk of thyroid cancer was increased
as a second cancer following breast cancer (OR = 1.55,
95% CI: 1.44–1.67). In the same metaanalysis, the risk of
breast cancer was also increased after thyroid cancer (OR
= 1.32, 95% CI: 1.23–1.42) [14].
In 2018, the incidence of all cancers in Turkey was
detected as 225.1 per 100,000 persons (0.2%) [15]. In
our study, a second primary malignancy was detected in
70 (5.9%) of 1196 patients with thyroid cancer. In our
study, the rate of second primary malignancy in patients
with thyroid cancer was detected to be higher than in
the general population. In our study, rates of breast, lung,
and colon cancers were found to be higher in patients
with thyroid cancer than in the general population. The
incidence of breast cancer in Turkey is 46.8 per 100,000
persons. In the study of Silva et al., breast cancer was
detected in 1.9% of 2031 differentiated thyroid cancer
patients [12]. In our study, breast cancer was detected in
2% of 1196 patients with thyroid cancer. The incidence
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of lung cancer in Turkey is 53.8 per 100,000 males and
8.2 per 100,000 females. In the study of Silva et al., lung/
pleural cancer was detected in 0.5% of 2031 differentiated
thyroid cancer patients [12]. In our study, lung cancer
was detected in 0.4% of 1196 patients with thyroid
cancer. The incidence of colon cancer in Turkey is 21.8
per 100,000 males and 13.2 per 100,000 females. In the
study of Silva et al., gastrointestinal tract cancer was
detected in 1.1% of 2031 differentiated thyroid cancer
patients [12]. In our study, colon cancer was detected in
0.4% of 1196 patients with thyroid cancer.
In a study conducted by Lang et al. with 895 thyroid
cancer patients, 643 (71.8%) of the patients received RAI
treatment. After a median follow-up of 93.5 months
(range: 23.4–570.8), 64 (7.2%) patients had developed
a second primary malignancy [14]. The risk of second
primary malignancy was significantly higher in the group
treated with RAI treatment than in the group without RAI
treatment. In their study, 80–240 mCi cumulative RAI
treatment dose was identified as the only independent
risk factor for second primary malignancies [14]. Of the
1196 patients included in our study, 855 (71.5%) received
RAI treatment and 341 (28.5%) did not. The median
dose of RAI treatment was 150 mCi (min–max: 100–
800) and mean RAI treatment dose was 146 ± 73 mCi.
Of the 70 patients with a second primary malignancy,
32 were diagnosed with thyroid cancer first and then
diagnosed with the second primary malignancy. Of these
32 patients, 25 received RAI treatment. The median RAI
dose of patients who received RAI was 150 mCi (min–
max: 100–650); mean RAI dose was 181 ± 144 mCi.
These patients were diagnosed with a second primary
malignancy after a median of 39 ± 33 months after
thyroid cancer diagnosis (median: 38 months, min–max:
1–118 months). Of the 70 patients with second primary
malignancy, 38 were diagnosed with malignancy prior
to thyroid cancer and 25 of these patients had RAI. The
median RAI dose of patients who received RAI was 150
mCi (min–max 100–400); mean RAI dose was 160 ±
68 mCi. There was no difference between patients with
another malignancy prior to thyroid cancer diagnosis
and those diagnosed with a second primary malignancy
after thyroid cancer diagnosis in terms of RAI dose (P =
0.473).
In conclusion, it was found that the most common
second primary malignancy in patients with thyroid
cancer was breast cancer, and many other cancers
(skin cancer, renal cell cancer, lymphoma, colon, lung,
and endometrial cancer) were also detected as second
primary cancer in patients with thyroid cancer. There
is a need for further studies with more cases and longer
follow-up.

KARAKÖSE et al. / Turk J Med Sci
References
1.

Cabanillas ME, McFadden DG, Durante C. Thyroid cancer.
Lancet 2016; 388 (10061): 2783-2795. doi: 10.1016/S01406736(16)30172-6

2.

3.

9.

Curado MP, Edwards B, Shin HR, Storm H, Ferlay J et
al. Cancer Incidence in Five Continents. No. 160. Vol. 9. Lyon,
France: IARC; 2007.

Goldman MB, Maloof F, Monson RR, Aschengrau A, Cooper
DS et al. Radioactive iodine therapy and breast cancer. A
follow-up study of hyperthyroid women. American Journal
of Epidemiology 1988; 127 (5): 969-980. doi: 10.1093/
oxfordjournals.aje.a114900

10.

Mazzaferri EL. Thyroid cancer. In Becker KL (editor).
Principles and Practice of Endocrinology and Metabolism, 3rd
Ed. Philadelphia, PA, USA: Lippincott, Williams & Wilkins;
2001. pp. 382-402.

Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski
M et al. CHEK2 is a multiorgan cancer susceptibility gene.
American Journal of Human Genetics 2004; 75 (6): 11311135. doi: 10.1086/426403

11.

Kumar A, Klinge CM, Goldstein RE. Estradiol-induced
proliferation of papillary and follicular thyroid cancer cells is
mediated by estrogen receptors alpha and beta. International
Journal of Oncology 2010; 36 (5): 1067-1080. doi: 10.3892/
ijo_00000588

4.

Sherman SI. Thyroid carcinoma. Lancet 2003; 361 (9356): 501511. doi: 10.1016/s0140-6736(03)12488-9

5.

Rosenberg SA. Cancer of the endocrine system. In: Devita
VT, Hellman S, Rosenberg SA (editors). Cancer: Principles
and Practice of Oncology. 8th Ed. Philadelphia, PA, USA:
Lippincott Williams & Wilkins; 2008. pp. 1655-1682.

12.

Fang Yu, Jinhua M, Huo K, Li P. Association between breast
cancer and thyroid cancer: a descriptive study. Translational
Cancer Research 2017; 6 (2): 393-401. doi: 10.21037/
tcr.2017.03.44

Silva-Vieira M, Carrilho Vaz S, Esteves S, Ferreira
TC, Limbert E et al. Second primary cancer in patients with
differentiated thyroid cancer: does radioiodine play a role?
Thyroid 2017; 27 (8): 1068-1076. doi: 10.1089/thy.2016.0655

13.

Izkhakov E, Barchana M, Liphshitz I, Silverman BG, Stern
N et al. Trends of second primary malignancy in patients
with thyroid cancer: a population-based cohort study in Israel.
Thyroid 2017; 27 (6): 793-801. doi: 10.1089/thy.2016.0481

14.

Nielsen SM, White MG, Hong S, Aschebrook-Kilfoy B, Kaplan
EL et al. The breast-thyroid cancer link: a systematic review
and meta-analysis. Cancer Epidemiology, Biomarkers &
Prevention 2016; 25 (2): 231-238. doi: 10.1158/1055-9965.EPI15-0833

15.

GLOBOCAN. Turkey Source: New Global Cancer Data. Lyon,
France: GLOBOCAN; 2018.

6.

7.

8.

Sandeep TC, Strachan MWJ, Reynolds RM, Brewster DH,
Scélo G et al. Second primary cancers in thyroid cancer
patients: a multinational record linkage study. Journal of
Clinical Endocrinology and Metabolism 2006; 91: 1819-1825.
doi: 10.1210/jc.2005-2009
Ronckers C, McCarron P, Ron E. Thyroid cancer and multiple
primary tumors in the SEER cancer registries. International
Journal of Cancer 2005; 117 (2): 281-288. doi: 10.1002/ijc.21064

1533

